General Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Propofol, Sevoflurane), By Route Of Administration (Intravenous, Inhaled), By End-use, By Application, By Region and Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Gastrointestinal Stents Market Growth & Trends
The global gastrointestinal stents market size is expected to reach USD 611.4 million by 2030, registering a CAGR of 5.2% during the forecast period, according to a new report by Grand View Research, Inc. Increasing burden of gastrointestinal diseases including biliary diseases, esophageal cancer, and colorectal cancer are anticipated to boost the usage of GI stents across the globe.
Individuals above 60 years of age form the key target population for these products, as they are at a high risk of developing gastrointestinal and stomach-related diseases. Thus, aging demographics of most of the economies around the globe is a prime factor driving the growth of the sector. Moreover, reimbursement coverage provided by the Center for Medicare & Medicaid Services (CMS) and various private payers is spurring the adoption of GI stents.
Gastrointestinal Stents Market Report Highlights
Gastrointestinal Stents Market Growth & Trends
The global gastrointestinal stents market size is expected to reach USD 611.4 million by 2030, registering a CAGR of 5.2% during the forecast period, according to a new report by Grand View Research, Inc. Increasing burden of gastrointestinal diseases including biliary diseases, esophageal cancer, and colorectal cancer are anticipated to boost the usage of GI stents across the globe.
Individuals above 60 years of age form the key target population for these products, as they are at a high risk of developing gastrointestinal and stomach-related diseases. Thus, aging demographics of most of the economies around the globe is a prime factor driving the growth of the sector. Moreover, reimbursement coverage provided by the Center for Medicare & Medicaid Services (CMS) and various private payers is spurring the adoption of GI stents.
Gastrointestinal Stents Market Report Highlights
- The gastrointestinal stents market study suggests that biliary stent dominated the overall sector in 2023. Incidences of biliary diseases such as bile duct cancer, gallstone disease and primary biliary cholangitis are on the rise globally, which would drive the growth of biliary stents sector positively.
- Duodenal stents are projected to emerge as the fastest-growing segment during the forecast period. Attributed to the rising gastrointestinal disorders such as tumors, strictures, and other pathologies.
- North America occupied the largest revenue share in 2023, due to the high rate of diagnosing new cases of gastrointestinal diseases and constantly rising awareness regarding commercial availability of effective treatments.
- In addition, increasing incidences of irritable bowel syndrome, colorectal cancer and pancreatic cancer are a few high impact-rendering drivers for the market.
- Asia Pacific is expected to witness a significant growth during the forecast period. The presence of countries such as Japan, China and India with constantly increasing patient population is a key factor anticipated to fuel the market growth in the region.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Route of Administration
1.2.3. End Use
1.2.4. Application
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Outlook
2.2.2. Route of Administration
2.2.3. End Use
2.2.4. Application
2.2.5. Regional outlook
2.3. Competitive Insights
CHAPTER 3. GENERAL ANESTHESIA DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Volume of Surgical Procedures
3.2.1.2. Advancements In Anesthesia Technology
3.2.1.3. Regulatory Developments
3.2.2. Market restraint analysis
3.2.2.1. Regulatory and Compliance Challenges
3.2.2.2. Adverse Effects and Safety Concerns
3.3. General Anesthesia Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. GENERAL ANESTHESIA DRUGS MARKET: DRUG ESTIMATES & TREND ANALYSIS
4.1. Global General Anesthesia Drugs Market: Drug Dashboard
4.2. Global General Anesthesia Drugs Market: Drug Movement Analysis
4.3. Global General Anesthesia Drugs Market by Drug, Revenue
4.4. Sevoflurane
4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Propofol
4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Dexmedetomidine
4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Remifentanil
4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Desflurane
4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Midazolam
4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Others
4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. GENERAL ANESTHESIA DRUGS MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
5.1. Global General Anesthesia Drugs Market: Route of Administration Dashboard
5.2. Global General Anesthesia Drugs Market: Route of Administration Movement Analysis
5.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
5.4. Intravenous
5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Inhaled
5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. GENERAL ANESTHESIA DRUGS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Global General Anesthesia Drugs Market: End Use Dashboard
6.2. Global General Anesthesia Drugs Market: End Use Movement Analysis
6.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
6.4. Hospitals
6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Ambulatory Surgical Centers
6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. GENERAL ANESTHESIA DRUGS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
7.1. Global General Anesthesia Drugs Market: Application Dashboard
7.2. Global General Anesthesia Drugs Market: Application Movement Analysis
7.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
7.4. Heart Surgeries
7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Cancer
7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
7.6. General Surgery
7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Knee and hip replacements
7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Other
7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. GENERAL ANESTHESIA DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG, ROUTE OF ADMINISTRATION, END USE AND APPLICATION
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Company/Competition Categorization
9.2. Vendor Landscape
9.2.1. List of key distributors and channel partners
9.2.2. Key company market share analysis, 2023
9.2.3. Baxter International Inc.
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Drug benchmarking
9.2.3.4. Strategic initiatives
9.2.4. AstraZeneca
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Drug benchmarking
9.2.4.4. Strategic initiatives
9.2.5. AbbVie Inc.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Drug benchmarking
9.2.5.4. Strategic initiatives
9.2.6. B. Braun Melsungen AG
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Drug benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Fresenius SE & Co. KgaA
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Drug benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Pfizer
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Drug benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Hospira Inc.
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Drug benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Aspen Pharmacare Holdings Limited
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Drug benchmarking
9.2.10.4. Strategic initiatives
9.2.11. Hikama Pharmaceuticals plc
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Drug benchmarking
9.2.11.4. Strategic initiatives
9.2.12. Abbott Laboratories
9.2.12.1. Company overview
9.2.12.2. Financial performance
9.2.12.3. Drug benchmarking
9.2.12.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Route of Administration
1.2.3. End Use
1.2.4. Application
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Outlook
2.2.2. Route of Administration
2.2.3. End Use
2.2.4. Application
2.2.5. Regional outlook
2.3. Competitive Insights
CHAPTER 3. GENERAL ANESTHESIA DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Volume of Surgical Procedures
3.2.1.2. Advancements In Anesthesia Technology
3.2.1.3. Regulatory Developments
3.2.2. Market restraint analysis
3.2.2.1. Regulatory and Compliance Challenges
3.2.2.2. Adverse Effects and Safety Concerns
3.3. General Anesthesia Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. GENERAL ANESTHESIA DRUGS MARKET: DRUG ESTIMATES & TREND ANALYSIS
4.1. Global General Anesthesia Drugs Market: Drug Dashboard
4.2. Global General Anesthesia Drugs Market: Drug Movement Analysis
4.3. Global General Anesthesia Drugs Market by Drug, Revenue
4.4. Sevoflurane
4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Propofol
4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Dexmedetomidine
4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Remifentanil
4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Desflurane
4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Midazolam
4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Others
4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. GENERAL ANESTHESIA DRUGS MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
5.1. Global General Anesthesia Drugs Market: Route of Administration Dashboard
5.2. Global General Anesthesia Drugs Market: Route of Administration Movement Analysis
5.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
5.4. Intravenous
5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Inhaled
5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. GENERAL ANESTHESIA DRUGS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Global General Anesthesia Drugs Market: End Use Dashboard
6.2. Global General Anesthesia Drugs Market: End Use Movement Analysis
6.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
6.4. Hospitals
6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Ambulatory Surgical Centers
6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. GENERAL ANESTHESIA DRUGS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
7.1. Global General Anesthesia Drugs Market: Application Dashboard
7.2. Global General Anesthesia Drugs Market: Application Movement Analysis
7.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
7.4. Heart Surgeries
7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Cancer
7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
7.6. General Surgery
7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Knee and hip replacements
7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Other
7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. GENERAL ANESTHESIA DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG, ROUTE OF ADMINISTRATION, END USE AND APPLICATION
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Company/Competition Categorization
9.2. Vendor Landscape
9.2.1. List of key distributors and channel partners
9.2.2. Key company market share analysis, 2023
9.2.3. Baxter International Inc.
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Drug benchmarking
9.2.3.4. Strategic initiatives
9.2.4. AstraZeneca
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Drug benchmarking
9.2.4.4. Strategic initiatives
9.2.5. AbbVie Inc.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Drug benchmarking
9.2.5.4. Strategic initiatives
9.2.6. B. Braun Melsungen AG
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Drug benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Fresenius SE & Co. KgaA
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Drug benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Pfizer
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Drug benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Hospira Inc.
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Drug benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Aspen Pharmacare Holdings Limited
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Drug benchmarking
9.2.10.4. Strategic initiatives
9.2.11. Hikama Pharmaceuticals plc
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Drug benchmarking
9.2.11.4. Strategic initiatives
9.2.12. Abbott Laboratories
9.2.12.1. Company overview
9.2.12.2. Financial performance
9.2.12.3. Drug benchmarking
9.2.12.4. Strategic initiatives
